# Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

> **NCT01206608** · PHASE2 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 40 (actual)

## Conditions studied

- Postoperative Pain

## Interventions

- **DRUG:** SKY0402 + bupivacaine HCl
- **DRUG:** Mid-dose SKY0402 + bupivacaine HCl

## Key facts

- **NCT ID:** NCT01206608
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-08
- **Final completion:** 2008-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206608, "Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01206608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*